Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib post-transplant shows favorable outcomes, including a 2-year overall survival rate of 90% vs historical benchmark of 51% –
– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who
resumed revumenib post-transplant shows favorable outcomes, including a
2-year overall survival rate of 90% vs historical benchmark of 51% –
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.